Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24913993 | 1.00 | SPR (0.38) | SPRTMEM97SIGMAR1KDM5APTGDR2 | |
| SCHEMBL30155831 | 1.00 | SPR (0.38) | SPRTMEM97SIGMAR1KDM5APTGDR2 | |
| SCHEMBL24913991 | 1.00 | SPR (0.38) | SPRTMEM97SIGMAR1KDM5APTGDR2 | |
| SCHEMBL30155752 | 0.95 | TMEM97 (0.36) | TMEM97SIGMAR1PTGDR2L3MBTL1 | |
| SCHEMBL30155749 | 0.95 | TMEM97 (0.36) | TMEM97SIGMAR1PTGDR2L3MBTL1 | |
| SCHEMBL24914229 | 0.95 | NSD2 (0.40) | TMEM97SIGMAR1PTGDR2NSD2BRD4 | |
| SCHEMBL30155850 | 0.95 | NSD2 (0.40) | TMEM97SIGMAR1PTGDR2NSD2BRD4 | |
| SCHEMBL24913891 | 0.95 | TMEM97 (0.38) | SPRTMEM97SIGMAR1PTGDR2PRMT5 | |
| SCHEMBL30155743 | 0.95 | TMEM97 (0.38) | SPRTMEM97SIGMAR1PTGDR2PRMT5 | |
| SCHEMBL30789144 | 0.94 | SPR (0.39) | SPRTMEM97SIGMAR1KDM5ANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | claimed |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | SPR 455/4885TMEM97 3224/4885SIGMAR1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.